Breaking News: Moleculin Receives Institutional Review Board Approval for Groundbreaking Phase 3 Trial of Annamycin and Cytarabine in Treating RR Acute Myeloid Leukemia (AML)
Exciting News in Cancer Treatment Company Leading the Way in AML Trials Recently, Moleculin Biotech, Inc. announced that it is on track to treat the first subject in its pivotal Phase 3 clinical trial in early 2025. This trial, known as the “MIRACLE” trial, is designed to potentially accelerate the approval of Annamycin in combination…